Article ; Online: Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.
The Journal of infectious diseases
2020 Volume 224, Issue 6, Page(s) 934–937
Abstract: Emerging data from open-label randomized trials without placebo controls suggest potential mortality benefits for combining corticosteroids with the interleukin 6 receptor antagonist tocilizumab in severe coronavirus disease 2019. Conversely, dual ... ...
Abstract | Emerging data from open-label randomized trials without placebo controls suggest potential mortality benefits for combining corticosteroids with the interleukin 6 receptor antagonist tocilizumab in severe coronavirus disease 2019. Conversely, dual immunomodulation may weaken antiviral responses and delay viral clearance, allowing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to expand its population and accrue genetic diversity within individual hosts. Generating a pool of hosts with genetically diverse viral populations while introducing new selective pressures in the form of vaccination-induced immunity could accelerate the process of antigenic drift in SARS-CoV-2. However, clinical trials to date have largely disregarded viral outcomes, and data on viral kinetics in response to immunomodulation are scarce. Coadministration of antiviral agents with immunomodulation could serve as a potential strategy to aid viral clearance and reduce the risk of genetic diversification. |
---|---|
MeSH term(s) | Adrenal Cortex Hormones/pharmacology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antiviral Agents/pharmacology ; COVID-19/drug therapy ; Dexamethasone/pharmacology ; Drug Combinations ; Humans ; Immunologic Factors ; SARS-CoV-2/drug effects |
Chemical Substances | Adrenal Cortex Hormones ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Drug Combinations ; Immunologic Factors ; Dexamethasone (7S5I7G3JQL) ; tocilizumab (I031V2H011) |
Language | English |
Publishing date | 2020-10-08 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 3019-3 |
ISSN | 1537-6613 ; 0022-1899 |
ISSN (online) | 1537-6613 |
ISSN | 0022-1899 |
DOI | 10.1093/infdis/jiab328 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uh II Zs.50: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 445: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.